Money, Multiples, & Margins: The Real State of ASC M&A in 2026
Money, Multiples, & Margins: The Real State of ASC M&A in 2026
In this episode of the Claims Theory Podcast, Lindsay sits down with Chad Zoretic of VMG Health to break down what is really happening in ambulatory surgery center M&A right now.
Are valuations stabilizing or compressing? What EBITDA multiples are buyers actually paying in 2026? Is this a buyer's market or a seller's market? And how much does revenue cycle performance really impact deal value?
Chad works at the intersection of ASCs, private equity, and high-level financial strategy. Together, the unpack:
Current ASC deal flow trends
EBITDA multiples for single-site vs. platform deals
What buyers are prioritizing right now
Financial red flags that kill valuation
How disciplined operations drive premium exits
Where the ASC market is headed over the next 3-5 years
If you own, operate, invest in, or advise ASCs, this is a must-listen.
Because in 2026, preparation is not optional.
Discipline drives valuation.
